Altogether, we showed that pharmacological inactivation of MCT1 or MCT4 inhibits the proliferation of leukemic cells in vitro, thus indicating that targeting lactate metabolism in AML may be an opportunity for novel treatment strategies in AMLs. The gene discussed is SLC16A3; the disease is acute myeloid leukemia.